Skip to main content
SpringerLink
Log in

HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients

  • Letter to the Editor
  • Published:
The Pharmacogenomics Journal Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Frías M, Rodríguez-Cano D, Cuenca-López F, Macías J, Gordon A, Manzanares-Martín B et al. HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy. Pharmacogenomics J, e-pub ahead of print 31 May 2016; doi: 10.1038/tpj.2016.42.

    Article  Google Scholar 

  2. Berenguer J, Zamora FX, Carrero A, Von Wichmann MA, Crespo M, López-Aldeguer J et al. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. J Acquir Immune Defic Syndr 2014; 66: 280–287.

    Article  CAS  Google Scholar 

  3. Labarga P, Fernandez-Montero JV, Barreiro P, Pinilla J, Vispo E, de Mendoza C et al. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy. J Viral Hepat 2014; 21: 475–479.

    Article  CAS  Google Scholar 

  4. Vergara S, Macías J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, Merino D et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45: 969–974.

    Article  Google Scholar 

  5. Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E et al. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology 2012; 56: 1681–1687.

    Article  CAS  Google Scholar 

  6. Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293–1302.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Laura Ruiz and Ismael Zafra for their technical support in this study. This study was funded by the Fundación Progreso y Salud, Consejería de Salud de la Junta de Andalucía (grants for health research projects: 0430/2012), the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo (ISCIII-RETIC RD06/006 and RD12/0017).

Author information

Authors and Affiliations

  1. Infectious Diseases Unit, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain

    M Frías, D Rodríguez-Cano, F Cuenca-López, A Gordon, Á Camacho, J Torre-Cisneros, A Rivero-Juárez & A Rivero

  2. Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, Seville, Spain

    J Macías & J A Pineda

  3. Immunology Unit, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain

    B Manzanares-Martín & J Peña

Authors
  1. M Frías
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Rodríguez-Cano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Cuenca-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Macías
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Manzanares-Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J A Pineda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Á Camacho
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Torre-Cisneros
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Peña
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Rivero-Juárez
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Rivero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Rivero-Juárez.

Ethics declarations

Competing interests

AR received consulting fees from Bristol-Myers Squibb, Abbott, Gilead, Roche, Boehringer Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme, and Janssen-Cilag. He also received lecture fees from GlaxoSmithKline, Roche, Abbott, Bristol-Myers Squibb, Boehringer Ingelheim and Schering-Plough. The remaining authors declare no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Frías, M., Rodríguez-Cano, D., Cuenca-López, F. et al. HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients. Pharmacogenomics J 17, 479–480 (2017). https://doi.org/10.1038/tpj.2016.80

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2016.80

  • Springer Nature Limited

Search

Navigation